Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
NICE Technology Appraisal guidance (TA875 for semaglutide/Wegovy and TA664 for liraglutide/Saxenda) recommends these medications for weight management in adults with: A body mass index (BMI) of at least 35 kg/m and At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease) For liraglutide (Saxenda), NICE TA664 specifies additional criteria including prediabetes (HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L) or high risk of cardiovascular disease
The buying decision comes down to reading the full listing, not just one number
Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence
Two groups were compared, one receiving a placebo and the other a 300mg iron sulphate capsule containing 80 mg of elemental iron
US$ 21.33
US$ 29.60
US$ 21.30
US$ 26.38
US$ 24.07
US$ 23.89
US$ 21.60
US$ 28.44
US$ 24.34
US$ 28.63
